From AVAC <[email protected]>
Subject Jan 13 Webinar – Ups & Downs in the Field: Setting an agenda together for 2022
Date January 7, 2022 1:14 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
------------------------------------------------------------
[link removed]


** Ups & Downs in the Field: Setting an agenda together for 2022
------------------------------------------------------------
January 7, 2022

Dear Advocate,

Join us Thursday, January 13 at 9:00 am EST for the Ups & Downs in the Field: Setting an Agenda Together for HIV Prevention in 2022 ([link removed]) , a webinar to discuss the latest advances, disappointments and opportunities in HIV prevention.

Register here ([link removed]) to join us in a lively conversation with Rachel Baggaley from the World Health Organization; Linda-Gail Bekker from South Africa’s Desmond Tutu Health Foundation; Grace Kumwenda of Pakachere Institute of Health and Development Communication; and Kenneth Mwehonge, the new executive director of Coalition for Health Promotion and Social Development (HEPS-Uganda).

[link removed]

2022 begins in the midst of possibility and uncertainty ([link removed]) . Some HIV prevention interventions are advancing at record speed while others face unexpected challenges. With lessons learned from oral PrEP, ([link removed]) new targets from UNAIDS ([link removed]) putting social drivers of epidemics in focus, and pioneering innovation ignited in the response to COVID-19 ([link removed]) , the ability is at hand to fundamentally impact the epidemic through primary prevention. It means offering a full spectrum of much needed prevention choices to the people who need them most. And it depends on the core priorities AVAC has long championed: follow the science, center communities in the response and lead with equity.

This webinar will provide an opportunity to address key questions including: where we are with the introduction of injectable CAB-LA ([link removed]) and the Dapivirine Vaginal Ring ([link removed]) ; the development statusof islatravir as a monthly pill ([link removed]) and injectable lenacapavir ([link removed]) as promising new PrEP agents whose trials were put on hold late in 2021 ([link removed]) ; and how to ensure HIV prevention, and equitable access to innovation, do not fall further behind; and much more.

Let’s start 2022 by coming together ([link removed]) to chart a shared agenda for HIV prevention and global health equity!

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Screenshot of the email generated on import

Message Analysis